The Medical Letter on Drugs and Therapeutics
Sugammadex (Bridion) for Rapid Reversal of Neuromuscular Blockade
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved sugammadex (Bridion – Merck), a selective relaxant binding agent, for reversal of rocuronium- or vecuronium-induced neuromuscular blockade in adult surgical patients. It is the first selective relaxant binding agent to be approved in the US. Sugammadex has been available in the European Union, Japan, and elsewhere for several years. Previous FDA reviews of sugammadex did not result in approval because of concerns about a risk of anaphylaxis and other hypersensitivity reactions with its use.

STANDARD TREATMENT — Rocuronium and vecuronium are steroidal nondepolarizing neuromuscular blocking agents; they have a slower onset and longer duration of action than the nonsteroidal depolarizing drug succinylcholine, but are less likely to cause serious adverse effects such as hyperkalemia and malignant hyperthermia. The acetylcholinesterase inhibitor neostigmine (Bloxiverz, and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sugammadex (Bridion) for Rapid Reversal of Neuromuscular Blockade
Article code: 1502c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian